AI-powered mobile app to support chemotherapy for breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial tests an Arabic-language AI mobile application designed to provide personalized chemotherapy support for women with breast cancer. The app offers medication reminders, side-effect management guidance, and real-time alerts to healthcare teams for serious symptoms, using NLP and a human-in-the-loop safety model. The study compares the AI-supported care plus usual oncology care versus usual care alone, focusing on safety, symptom burden, adherence, and satisfaction with information. Participants must be adults with breast cancer starting their first chemotherapy cycle and able to use a smartphone in Arabic. The intervention emphasizes local guidelines and CTCAE-based triage to balance autonomous guidance with clinician oversight.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of breast cancer stages I, II, or III.
* Patients must be currently scheduled to initiate their first-ever cycle of chemotherapy.
* Age 18 years or older.
* Ability to understand and provide informed consent.
* Possession of a smartphone (Android or iOS) and functional digital literacy, defined as the ability to independently navigate mobile applications, read on-screen text in Arabic, and input daily health data. (for the intervention group).
* Willingness to comply with study procedures and follow-up schedules.
* Ability to communicate in Arabic, as the mobile application and chatbot will be developed in Arabic.

Exclusion Criteria:

* Patients with Stage IV (Metastatic) breast cancer.
* Patients receiving concurrent hormonal therapy during the chemotherapy phase, to isolate chemotherapy-induced adverse events.

Patients with cognitive impairment or severe psychiatric disorders that would preclude effective interaction with the mobile application or questionnaire completion.

* Patients receiving palliative care where symptom management is the sole focus and active chemotherapy is not being administered with curative or life prolonging intent.
* Patients participating in other interventional clinical trials that might confound the outcomes of this study.
* Patients with severe comorbidities that could significantly impact their ability to participate or bias outcome measures.

Where it's running

• Oncology Teaching Hospital-Medical City- Baghdad
  Baghdad, Iraq Recruiting

Study contacts

• Principal investigator: Samer Imad Mohammed, Assistant Prof — University of Baghdad-College of Pharmacy
• Study coordinator: Dena A. Al-Tameemi, MSc.
• Email: dina.abbas2400p@copharm.uobaghdad.edu.iq
• Phone: +9647901572647

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cryoablation for small breast tumors (SIX)

  This study will test whether cryoablation works as well as standard breast surgery for people with small (≤2.0 cm), unifocal early-stage breast cancer and will compare direct costs over one year.

  Recruiting Phase 3 Hospital do Coracao · São Paulo, São Paulo and 1 other locations · NCT06839001

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Using tart cherry juice to prevent nerve damage from chemotherapy in breast cancer patients

  This study is testing if drinking tart cherry juice can help prevent nerve damage in breast cancer patients receiving chemotherapy.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06268665

• Oral MBQ-167 treatment for advanced breast cancer

  This study is testing a new oral medication called MBQ-167 to see if it can help people with advanced breast cancer who haven't had success with other treatments.

  Recruiting at 3 sites Phase 1 MBQ Pharma · Beverly Hills, California and 3 other locations · NCT06075810

• Evaluating Bria-IMT with Checkpoint Inhibitor for Advanced Metastatic Breast Cancer

  This study is testing if a new treatment combining Bria-IMT with a checkpoint inhibitor can help people with advanced metastatic breast cancer live longer compared to other treatments their doctors might choose.

  Recruiting at 79 sites Phase 3 BriaCell Therapeutics Corporation · Phoenix, Arizona and 78 other locations · NCT06072612

• Precision therapy for advanced breast cancer patients

  This study is testing different targeted treatments for patients with advanced breast cancer who have already tried certain medications, to see if personalized options can help them feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05594095

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.